Skip to main
INAB
INAB logo

IN8BIO (INAB) Stock Forecast & Price Target

IN8BIO (INAB) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 86%
Buy 0%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

IN8bio Inc shows a positive outlook due to the encouraging data surrounding its product candidate INB-100, which demonstrates a strong efficacy in preventing relapse in high-risk acute myeloid leukemia (AML) patients post-haploidentical stem cell transplantation. Notable metrics include a 100% overall survival rate at one year for patients treated with INB-100 compared to approximately 70% in historical studies, reflecting a significant improvement in treatment outcomes. Furthermore, the absence of treatment-related deaths and severe adverse events underscores the tolerability and safety profile of INB-100, reinforcing potential for successful clinical advancement and market acceptance.

Bears say

The analysis of IN8bio Inc reveals a downward adjustment in the 12-month price target from $8.00 to $6.00, indicating a cautious approach towards the stock's future performance. Despite the promising data from preclinical studies on the potential of INB-619, the overall market sentiment remains negative, potentially due to uncertainties surrounding the clinical progression of its product candidates. The focus on niche applications within oncology combined with potential challenges in commercialization may contribute to this unfavorable outlook.

IN8BIO (INAB) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 86% of analysts recommend a Strong Buy, 0% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of IN8BIO and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About IN8BIO (INAB) Forecast

Analysts have given IN8BIO (INAB) a Strong Buy based on their latest research and market trends.

According to 7 analysts, IN8BIO (INAB) has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

IN8BIO (INAB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.